Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Paclitaxel/Cisplatin
DRUG
3 trials
Sponsors
University of Erlangen-Nürnberg Medical School
, Mian XI
, Jianhua Fu
Conditions
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Head and Neck Cancer
Resectable Esophageal Cancer
Unresectable Esophageal Cancer
Phase 2
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
NCT04006041
Jianhua Fu
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Resectable Esophageal Cancer
Start: 2019-06-25
End: 2020-12-31
Target: 44
Updated: 2019-12-26
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Completed
NCT04005170
Mian XI
Unresectable Esophageal Cancer
Start: 2019-06-25
End: 2022-07-31
Updated: 2022-08-23
Phase 3
Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer
Terminated
NCT01126216
University of Erlangen-Nürnberg Medical School
Head and Neck Cancer
Start: 2010-06-30
End: 2019-06-30
Updated: 2021-05-04
Related Papers
Three-year outcomes and multi-omics biomarker discovery of locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and anti-PD-1 antibody from the phase II trial NEOCRTEC1901.
Journal of Clinical Oncology
2026-01-10
Impaired TGF-β signaling via AHNAK family mutations elicits an esophageal cancer subtype with sensitivities to genotoxic therapy and immunotherapy.
2024-09-05
1 citations
Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial.
2024-08-30
4 citations
Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab
Nature Communications
2024-03-01
21 citations
A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901).
2023-07-26
28 citations
Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).
Journal of Clinical Oncology
2023-06-01
2 citations
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
2023-04-01
65 citations
Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
2021-11-10
23 citations
The efficacy and safety of toripalimab combined with definitive chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
Journal of Clinical Oncology
2021-05-20
3 citations
A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Journal of Thoracic Disease
2020-11-01
42 citations
Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial.
2020-02-07
28 citations
Randomised phase-III-trial of concurrent chemoradiation (CRT) for locally advanced head and neck cancer (stage III-IVB): Comparing dose reduced radiotherapy (63,6 Gy) with paclitaxel/cisplatinum to standard radiotherapy (70,6 Gy) with fluorouracil/cisplatinum.
Journal of Clinical Oncology
2017-05-20
5 citations